ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01874483
Recruitment Status : Completed
First Posted : June 11, 2013
Last Update Posted : January 27, 2016
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004 following multiple dose administration over 14 days.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Placebo Drug: BI 187004 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)
Study Start Date : June 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: BI 187004 dose 1
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 1
Experimental: BI 187004 dose 2
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 2
Experimental: BI 187004 dose 3
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 3
Experimental: BI 187004 dose 4
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 4
Experimental: BI 187004 dose 5
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 5
Experimental: BI 187004 dose 6
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 6
Placebo Comparator: Placebo
placebo
Drug: Placebo
placebo
Experimental: BI 187004 dose 7
multiple dose given over 14 days
Drug: BI 187004
BI 187004, dose 7



Primary Outcome Measures :
  1. Occurrence of adverse events [ Time Frame: up to 15 days postdose ]

Secondary Outcome Measures :
  1. AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose) [ Time Frame: up to 8 days postdose ]
  2. Cmax t,1 (maximum measured concentration of the analyte in plasma after administration of the first dose) [ Time Frame: up to 8 days postdose ]
  3. AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) [ Time Frame: up to 8 days postdose ]
  4. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) [ Time Frame: up to 8 days postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Type 2 diabetes mellitus
  2. Current treatment with no more than one anti-diabetic drug (except for insulin and GLP-1 analogues)
  3. Males or post-menopausal or surgically sterilised females
  4. Age from 20 and to 70 years
  5. HbA1c less or equal to 8.5%
  6. BMI 28-40 kg/m2
  7. Subjects must be able to understand an comply with study requirements

Exclusion criteria:

  1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal that the investigator considers to be of not acceptable clinical relevance
  2. Repeated measurement of systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 95 mm Hg
  3. Myocardial infarction, stroke or transient ischemic attack within 6 months prior to informed consent
  4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia or medically treated hypertension
  5. Surgery of the gastrointestinal tract that might affect absorption and elimination of the study drug
  6. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy
  7. Chronic or relevant acute infections (e.g. HIV, hepatitis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874483


Locations
Germany
1307.2.1 Boehringer Ingelheim Investigational Site
Neuss, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Additional Information:
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01874483     History of Changes
Other Study ID Numbers: 1307.2
2013-000312-21 ( EudraCT Number: EudraCT )
First Posted: June 11, 2013    Key Record Dates
Last Update Posted: January 27, 2016
Last Verified: January 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases